Influence of related factors on the first results of peripheral blood hematopoietic stem cell mobilization in lymphoma patients

doi:10.12307/2022.002

Abstract

Abstract: BACKGROUND: The effect of hematopoietic stem cell collection is affected by a variety of factors, but the clear influencing factors have not yet been determined. It is necessary to continuously explore the risk factors that may affect the collection of hematopoietic stem cells.
OBJECTIVE: To investigate the influence of related factors on the first results of hematopoietic stem cell mobilization in peripheral blood of 50 patients with malignant lymphoma, and to explore the relationship between results and hematopoietic reconstruction after transplantation.
METHODS: Totally 50 lymphoma patients undergoing autologous peripheral blood hematopoietic stem cell transplantation from January 2015 to January 2020 were included in this study so as to analyze the age, stage, bone marrow invasion, recurrence, radiotherapy, granulocyte colony-stimulating factor duration, chemotherapy duration and other factors on the first hematopoietic stem cell collection, and to explore the relationship of collection results with neutrophile granulocyte and platelet implantation.
RESULTS AND CONCLUSION: The number of chemotherapy courses was negatively correlated with the collected CD34+ cell count. The results of hematopoietic stem cell collection were poor in patients with recurrence before transplantation, and among the radiotherapy patients, mobilization failure was relatively high, with a failure rate of 88.9%. Radiotherapy had a negative effect on hematopoietic stem cell collection. The higher the CD34+ cell count, the faster the neutrophile granulocyte implantation. However, the effect on post-transplantation platelet implantation was not so significant, but there was a trend. There was no difference in the number of CD34+ cells collected between granulocyte colony-stimulating factor duration of 1-5 days and granulocyte colony-stimulating factor duration of over 5 days. The results concluded that in lymphoma patients, excessive chemotherapy, recurrence and radiotherapy experience will obviously cause damage to hematopoietic stem cells. Radiotherapy should be performed after hematopoietic stem cell collection to avoid damage to hematopoietic stem cells.

Key words: lymphoma, CD34⁺ cells, autologous hematopoietic stem cell, peripheral blood, mobilization, collection, hematopoietic reconstitution

CLC Number:

Guo Qiuxia, Wang Jigang. Influence of related factors on the first results of peripheral blood hematopoietic stem cell mobilization in lymphoma patients[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(1): 7-11.

Figures/Tables 6

References

[1] HÜBEL K, DE LA RUBIA J, AZAR N, et al. Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. Eur J Haematol. 2015;94(1):12-22.
[2] LAHOUD OB, SAUTER CS, HAMLIN PA, et al. High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma. Curr Oncol Rep. 2015;17(9):42.
[3] COTTLER-FOX M, LAPIDOT T. Mobilizing the older patient with myeloma. Blood Rev. 2006;20(1):43-50.
[4] GERTZ MA, WOLF RC, MICALLEF IN, et al. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant. 2010;45(9):1396-1403.
[5] ZHENG G, HE J, CAI Z, et al. A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma. Oncol Lett. 2020;19(1):1051-1059.
[6] CALADO RT, YOUNG NS. Telomere maintenance and human bone marrow failure. Blood. 2008;111(9):4446-4455.
[7] AKHTAR S, WESHI AE, RAHAL M, et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma. 2008;49(4):769-778.
[8] 孙巍,高敏,谢嵘,等.151例淋巴瘤外周血造血干细胞采集影响因素分析[J].中国实验血液学杂志,2016,24(2):416-421.
[9] 熊艺颖,刘林,唐晓琼,等.48例非霍奇金淋巴瘤患者自体外周造血干细胞动员采集的影响因素分析[J].重庆医学,2017,46(24):3328-3331.
[10] POPAT U, SALIBA R, THANDI R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(6):718-723.
[11] TO LB, LEVESQUE JP, HERBERT KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530-4540.
[12] DERENZINI E, STEFONI V, MAGLIE R, et al. Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. Biol Blood Marrow Transplant. 2013;19(12):1695-1701.
[13] OZKURT ZN, YEGIN ZA, SUYANI E, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher. 2010;25(5):280-286.
[14] HILL BT, RYBICKI L, SMITH S, et al. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. Leuk Lymphoma. 2011;52(6):986-993.
[15] LEE KH, JUNG SK, KIM SJ, et al. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. Vox Sang. 2014;107(4):407-415.
[16] 王倩,袁磊,李红华,等.单中心191例健康供者应用G-CSF动员造血干细胞的影响因素分析[J].中国实验血液学杂志,2013,21(1):169-172.
[17] STIFF PJ, MICALLEF I, NADEMANEE AP, et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant. 2011;17(8):1146-1153.
[18] BOLWELL BJ, POHLMAN B, RYBICKI L, et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2007;40(5):437-441.
[19] HAN X, MA L, ZHAO L, et al. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study. J Clin Apher. 2012;27(2):64-74.
[20] HOSING C, SALIBA RM, AHLAWAT S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol. 2009;84(6):335-337.
[21] 常英军,赵翔宇,霍明瑞,等.rhG-CSF动员的骨髓和外周血干细胞混合移植物首次采集时供者外周血单核细胞计数反映混合采集物中CD34 +细胞含量[J].中国实验血液学杂志,2009,17(1):146-150.
[22] KURNAZ F, KAYNAR L. Peripheral blood stem cell mobilization failure. Transfus Apher Sci. 2015;53(1):3-7.
[23] DUARTE FB, PRADO BP, VIEIRA GM, et al. Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations. Rev Assoc Med Bras (1992). 2016;62 Suppl 1:10-15.
[24] LASZLO D, MARCACCI GP, MARTINO M, et al. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. Transfus Apher Sci. 2020;59(5):102819.
[25] VAN DE WYNGAERT Z, NERICH V, FOUQUET G, et al. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. Bone Marrow Transplant. 2020;55(12):2254-2260.

(责任编辑：MZH，ZN，JY)